Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Aspirin
3. Aspirin-exacerbated respiratory disease (AERD)
4. What we know about AERD
5. AERD before and after sensitization
6. Segmental lysine aspirin challenge
7. Urinary LTE4 after aspirin
8. Urinary LTE4
9. Excess cysteinyl leukotrienes
10. Genetic regulation of LTC4 synthase activity
11. Cysteinyl leukotriene receptors
12. Airways responsiveness to LTE4
13. AERD involvement in LTE4 abnormalities
14. Outline of eicosanoid metabolism (1)
15. Bronchial mucosal LTC4 synthase expression
16. AERD and prostanoids
17. Outline of eicosanoid metabolism (2)
18. PGE2 and leukotriene inhibition (1)
19. Inhaled PGE2 abrogates bronchospasm
20. Inhaled PGE2 increases in urinary LTE4
21. Other effects of PGE2
22. PGE2 and leukotriene inhibition (2)
23. Airways COX-1 expression in asthma
24. Airways COX-2 expression in asthma
25. COX-2 inhibitors in aspirin sensitive asthma
26. Urinary LTE4 excretion following challenge
27. PGE2 and leukotriene inhibition (3)
28. PGE2 production by fibroblast lines (2-3 weeks)
29. PGE2 production by nasal epithelial lines (6 days)
30. PGE2 and leukotriene inhibition (4)
31. EP receptors expression
32. Hypothesis
33. CysLT1/2 and EP-1/2/3/4 receptors
34. Global submucosal staining
35. Immunoreactive inflammatory cells percentage
36. The EP2 receptor alone is immunomodulatory
37. Are there more LTE to be found?
38. Data replication
39. Biopsy stained with antibodies
40. Double immunohistochemistry
41. Results for EP1 and EP2
42. Results for EP3 and EP4
43. PGE2 and leukotriene inhibition (5)
44. Summary: what we know
45. Summary: what we still don't know
46. Collaborators
47. Thank you for your kind attention

Topics Covered

• Clinical features
• AERD as a disease of excessive leukotriene production
• Alterations in eicosanoid metabolism
• The protective role of Prostaglandin E2 (PGE2)
• Reduced PGE2 signalling as a mechanism for AERD
• The PGE2 receptor EP2 as a molecular target

Links

Series:

• Advances in Asthma

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on December 27, 2012
• Reviewed on April 12, 2022

Financial Disclosures

• Prof. Chris Corrigan has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.